Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus. Issue 5 (4th May 2017)

• Record Type: Journal Article
• Authors: Albone, Earl F.; Spidel, Jared L.; Cheng, Xin; Park, Young Chul; Jacob, Sara; Milinichik, Andrew Z.; Vaessen, Ben; Butler, Janet; Kline, J. Bradford; Grasso, Luigi
• Is Part Of: Cancer biology & therapy. Volume 18:Issue 5(2017)
• Page Start: 347
• Page End: 357
• Publication Date: 2017-05-04
• Subjects: ADC -- auristatin -- bispecific -- chimeric -- disulfide -- immunoconjugate -- mesothelin -- site-specific; 616.99406
• DOI: 10.1080/15384047.2017.1312232
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: The conjugation of toxins, dyes, peptides, or proteins to monoclonal antibodies is often performed via free thiol groups generated by either partial reduction methods or engineering free cysteine residues into the antibody sequence. Antibodies from the rabbit Oryctolagus cuniculus have an additional intrachain disulfide bond, whereby the light chain variable kappa domain is bridged to the constant kappa region between cysteine residues at positions 80 and 171, respectively. Chimerization of rabbit antibodies with human constant domains allows for the generation of a free thiol group at the light chain position 80 (C80) that can be used for site-specific conjugation. An efficient process for the purification and simultaneous removal of cysteinylation at the C80 site was developed. The unpaired C80 was shown to be efficiently conjugated using several different maleimido-based ligands. REsidue SPEcific Conjugation Technology (RESPECT) antibody-drug conjugates prepared using rabbit-human chimeric anti-human mesothelin rabbit antibodies and maleimido-PEG2 -auristatin conjugated to C80 were shown to be highly potent and specific in vitro and effective in vivo in reduction of tumor growth in a highly aggressive mesothelin-expressing xenograft tumor model.